ECSP20067968A - Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos - Google Patents

Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos

Info

Publication number
ECSP20067968A
ECSP20067968A ECSENADI202067968A ECDI202067968A ECSP20067968A EC SP20067968 A ECSP20067968 A EC SP20067968A EC SENADI202067968 A ECSENADI202067968 A EC SENADI202067968A EC DI202067968 A ECDI202067968 A EC DI202067968A EC SP20067968 A ECSP20067968 A EC SP20067968A
Authority
EC
Ecuador
Prior art keywords
peptide
tyrosine
conjugates
glp
glucagon
Prior art date
Application number
ECSENADI202067968A
Other languages
English (en)
Inventor
Raul Camacho
Ellen Chi
Suzanne Edavettal
Mark Wall
Martin A Case
Rui Zhang
Wilson Edwards
Lisa Norquay
Songmao Zheng
Yue-Mei Zhang
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ECSP20067968A publication Critical patent/ECSP20067968A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención comprende conjugados que comprenden un péptido de fusión péptido similar al glucagón 1 (GLP-1) acoplado a un péptido PYY cíclico. La invención también se relaciona con composiciones farmacéuticas y con métodos para usarlas. Los conjugados novedosos son útiles para prevenir, tratar o corregir enfermedades y trastornos descritos en la presente descripción.
ECSENADI202067968A 2018-04-25 2020-10-23 Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos ECSP20067968A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862662313P 2018-04-25 2018-04-25
US2018029284 2018-04-25
PCT/IB2019/053384 WO2019207505A1 (en) 2018-04-25 2019-04-24 Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof

Publications (1)

Publication Number Publication Date
ECSP20067968A true ECSP20067968A (es) 2020-11-30

Family

ID=66676857

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202067968A ECSP20067968A (es) 2018-04-25 2020-10-23 Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos

Country Status (24)

Country Link
EP (1) EP3784692A1 (es)
JP (1) JP2021522258A (es)
KR (1) KR20210005674A (es)
CN (1) CN112004822A (es)
AU (2) AU2019259790B2 (es)
BR (1) BR112020021562A2 (es)
CA (1) CA3096792A1 (es)
CL (1) CL2020002718A1 (es)
CO (1) CO2020013221A2 (es)
CR (1) CR20200487A (es)
DO (1) DOP2020000192A (es)
EC (1) ECSP20067968A (es)
IL (1) IL278197A (es)
JO (1) JOP20200265A1 (es)
MA (1) MA52361A (es)
MX (1) MX2020011293A (es)
NI (1) NI202000071A (es)
PE (1) PE20211457A1 (es)
PH (1) PH12020551659A1 (es)
SA (1) SA520420401B1 (es)
SG (1) SG11202009844SA (es)
TW (1) TW202014433A (es)
UY (1) UY38200A (es)
WO (1) WO2019207505A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190095A1 (ar) * 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
CN116478298A (zh) * 2021-12-31 2023-07-25 广东东阳光药业有限公司 Glp-1和gdf15的融合蛋白及其用途
WO2024038067A1 (en) 2022-08-18 2024-02-22 Boehringer Ingelheim International Gmbh Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists
CN117327200B (zh) * 2023-11-28 2024-02-09 西宝生物科技（上海）股份有限公司 一种调控糖脂代谢和抗衰老的双功能重组蛋白gik及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103897066A (zh) * 2004-02-11 2014-07-02 安米林药品有限责任公司 具有可选择特性的杂合多肽
EA011860B1 (ru) * 2004-03-17 2009-06-30 7ТиЭм ФАРМА А/С Селективные агонисты рецептора y2 для терапевтического воздействия
AU2005311099B2 (en) * 2004-12-02 2012-02-02 Domantis Limited Bispecific domain antibodies targeting serum albumin and GLP-1 or PYY
WO2007018619A2 (en) * 2005-07-29 2007-02-15 Amprotein Corporation Chimeric therapeutic agents
CN101296942A (zh) * 2005-08-11 2008-10-29 安米林药品公司 具有可选择特性的杂合多肽
JP5399244B2 (ja) * 2006-08-17 2014-01-29 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー 選択可能な特性を持つｄｐｐ−ｉｖ耐性ｇｉｐハイブリッドポリペプチド
US8299023B2 (en) * 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
CA2774552A1 (en) * 2009-09-30 2011-04-07 Glaxo Group Limited Drug fusions and conjugates with extended half life
AU2016343775B2 (en) * 2015-10-28 2021-07-29 Tufts Medical Center Novel polypeptides with improved proteolytic stability, and methods of preparing and using same
JOP20190095A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y

Also Published As

Publication number Publication date
AU2019259790A1 (en) 2020-10-22
MA52361A (fr) 2021-03-03
JP2021522258A (ja) 2021-08-30
SG11202009844SA (en) 2020-11-27
TW202014433A (zh) 2020-04-16
EP3784692A1 (en) 2021-03-03
KR20210005674A (ko) 2021-01-14
DOP2020000192A (es) 2021-04-30
CA3096792A1 (en) 2019-10-31
CN112004822A (zh) 2020-11-27
BR112020021562A2 (pt) 2021-03-02
AU2023274117A1 (en) 2023-12-21
SA520420401B1 (ar) 2023-01-26
AU2019259790B2 (en) 2023-08-31
PE20211457A1 (es) 2021-08-05
MX2020011293A (es) 2020-11-13
CR20200487A (es) 2021-03-11
CL2020002718A1 (es) 2021-01-29
CO2020013221A2 (es) 2020-11-10
IL278197A (en) 2020-11-30
NI202000071A (es) 2021-01-21
JOP20200265A1 (ar) 2020-10-21
PH12020551659A1 (en) 2021-07-26
UY38200A (es) 2019-10-31
WO2019207505A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
ECSP20067968A (es) Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos
CO2019004203A2 (es) Compuestos del péptido tirosina tirosina cíclico con anticuerpo acoplado como moduladores de receptores de neuropéptido y
CL2021001430A1 (es) Composiciones de glp-1 y sus usos. (divisional de solicitud 202000422)
CO2017004489A2 (es) Polipéptidos fgf-21 modificados
GT201500049A (es) Proteinas de fusiòn para el tratamiento de un sìndrome metàbolico
BR112019000528A2 (pt) distribuição mediada por ve de conjugados de proteína de ligação-molécula pequena
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
CL2021000938A1 (es) Composiciones estables de semaglutida y usos de las mismas
EA202091095A1 (ru) Пероральная доставка пептидных аналогов glp-1
MX9302475A (es) Polipeptido de origen no natural que tiene la actividad del factor recombinante de estimulacion del receptor neu y proceso para la produccion del mis mo.
ECSP20020949A (es) Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos
PH12021551243A1 (en) Oxyntomodulin peptide analog formulations
AR114291A1 (es) Conjugados de péptido tirosina tirosina cíclico con péptido de fusión del péptido similar al glucagón tipo 1 (glp-1) acoplado y usos de estos
EA202092547A1 (ru) Связанные со слитым пептидом, содержащим глюкагонподобный пептид 1 (glp-1), циклические пептидные тирозинтирозиновые конъюгаты и их применение
EA202290107A1 (ru) Фармацевтические композиции на основе пептидов, являющихся коагонистами глюкагона и glp-1
UY36020A (es) Antígeno de inhibina alfa, gen codificante de inhibina alfa, gen codificante de proteína de fusión, proceso de obtención del antígeno de inhibina alfa, composición antigénica, uso del antígeno de inhibina alfa y uso de la composición antigénica